Neumora Therapeutics Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar '26 Mar 31, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Net Income	-222.39	-236.93	-243.79	-235.93	-130.9	-237.31
Depreciation & Amortization	0.06	0.21	0.63	0.67	0.59	0.54
Stock-Based Compensation	27.96	29.88	39.99	17.24	8.3	4.27
Other Adjustments	0.57	0.84	-2.41	63.64	14.06	158.04
Changes in Accounts Payable	4	0.07	2.87	-0.58	-1.25	-0.76
Changes in Accrued Expenses	-1.5	4.2	7.24	6.49	-1.62	6.56
Changes in Other Operating Activities	-3.15	-4.7	12.53	-14.8	-4.08	-6.76
Operating Cash Flow	-193.4	-206.44	-182.94	-163.28	-114.9	-75.42
Capital Expenditures	-	-	-	-0.12	-0.51	-0.82
Sale of Property, Plant & Equipment	0.29	0.22	-	-	-	-
Purchases of Investments	-38.48	-82.87	-312.22	-109.07	-226.37	-
Proceeds from Sale of Investments	162.63	251.17	242.44	178.17	71.87	-
Payments for Business Acquisitions	-	-	-0.78	-4.59	-13	-
Investing Cash Flow	124.43	168.52	-70.56	64.39	-168.01	-0.82
Long-Term Debt Issued	47.96	57.16	-	-	-	-
Net Long-Term Debt Issued (Repaid)	47.96	57.16	-	-	-	-
Issuance of Common Stock	11.12	19.93	21.6	236.23	4.27	3.47
Repurchase of Common Stock	-	-	-	-0.49	-	-
Net Common Stock Issued (Repurchased)	11.12	19.93	21.6	235.74	4.27	3.47
Issuance of Preferred Stock	-	-	-	-	112.22	291.18
Net Preferred Stock Issued (Repurchased)	-	-	-	-	112.22	291.18
Other Financing Activities	-	-	-	-3.8	-0.74	-1.14
Financing Cash Flow	87.96	77.09	21.6	231.94	115.74	293.51
Net Cash Flow	19	39.17	-231.89	133.05	-167.17	217.27
Free Cash Flow	-193.4	-206.44	-182.94	-163.4	-115.41	-76.24
Free Cash Flow Per Share	-1.15	-1.26	-1.15	-2.51	-4.24	-3.48
Levered Free Cash Flow	-175.02	-180	-220.52	-244.27	-137.77	-238.55
Unlevered Free Cash Flow	-223.73	-241.52	-240.39	-260.73	-142.74	-238.56

SEC Filings: 10-K · 10-Q